GLYMAXAN Trademark

Trademark Overview

On Friday, March 18, 2016, a trademark application was filed for GLYMAXAN with the United States Patent and Trademark Office. The USPTO has given the GLYMAXAN trademark a serial number of 86945019. The federal status of this trademark filing is ABANDONED - NO STATEMENT OF USE FILED as of Monday, February 10, 2020. This trademark is owned by Teva Pharmaceuticals USA, Inc.. The GLYMAXAN trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations for the treatment of pain, anti-virals, cardiovascular diseases, respiratory diseases, women's health, central nervous system disorders, gastrointestinal diseases, immunosuppressant, corticosteroids, metabolic syndrome, oncology and endocrinology
glymaxan

General Information

Serial Number86945019
Word MarkGLYMAXAN
Filing DateFriday, March 18, 2016
Status606 - ABANDONED - NO STATEMENT OF USE FILED
Status DateMonday, February 10, 2020
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, November 15, 2016

Trademark Statements

Goods and ServicesPharmaceutical preparations for the treatment of pain, anti-virals, cardiovascular diseases, respiratory diseases, women's health, central nervous system disorders, gastrointestinal diseases, immunosuppressant, corticosteroids, metabolic syndrome, oncology and endocrinology

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateWednesday, March 23, 2016
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameTeva Pharmaceuticals USA, Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressNorth Wales, PA 19454
Party NameTeva Pharmaceuticals USA, Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressNorth Wales, PA 19454

Trademark Events

Event DateEvent Description
Monday, February 10, 2020ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Monday, February 10, 2020ABANDONMENT - NO USE STATEMENT FILED
Wednesday, July 10, 2019NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, July 9, 2019EXTENSION 5 GRANTED
Tuesday, July 2, 2019EXTENSION 5 FILED
Saturday, July 6, 2019CASE ASSIGNED TO INTENT TO USE PARALEGAL
Tuesday, July 2, 2019TEAS CHANGE OF CORRESPONDENCE RECEIVED
Tuesday, July 2, 2019TEAS EXTENSION RECEIVED
Wednesday, January 9, 2019NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, January 7, 2019EXTENSION 4 GRANTED
Monday, January 7, 2019EXTENSION 4 FILED
Monday, January 7, 2019TEAS EXTENSION RECEIVED
Wednesday, July 4, 2018NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, July 2, 2018EXTENSION 3 GRANTED
Monday, July 2, 2018EXTENSION 3 FILED
Monday, July 2, 2018TEAS EXTENSION RECEIVED
Monday, July 2, 2018TEAS CHANGE OF CORRESPONDENCE RECEIVED
Friday, January 5, 2018NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, January 3, 2018EXTENSION 2 GRANTED
Wednesday, January 3, 2018EXTENSION 2 FILED
Wednesday, January 3, 2018TEAS EXTENSION RECEIVED
Friday, July 7, 2017NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, July 5, 2017EXTENSION 1 GRANTED
Wednesday, July 5, 2017EXTENSION 1 FILED
Wednesday, July 5, 2017TEAS EXTENSION RECEIVED
Tuesday, January 10, 2017NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, November 15, 2016OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, November 15, 2016PUBLISHED FOR OPPOSITION
Wednesday, October 26, 2016NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Monday, October 3, 2016APPROVED FOR PUB - PRINCIPAL REGISTER
Monday, September 19, 2016EXAMINER'S AMENDMENT ENTERED
Monday, September 19, 2016NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Monday, September 19, 2016EXAMINERS AMENDMENT E-MAILED
Monday, September 19, 2016EXAMINERS AMENDMENT -WRITTEN
Friday, September 16, 2016TEAS/EMAIL CORRESPONDENCE ENTERED
Friday, September 16, 2016CORRESPONDENCE RECEIVED IN LAW OFFICE
Friday, September 16, 2016TEAS RESPONSE TO OFFICE ACTION RECEIVED
Wednesday, April 6, 2016NOTIFICATION OF PRIORITY ACTION E-MAILED
Wednesday, April 6, 2016PRIORITY ACTION E-MAILED
Wednesday, April 6, 2016PRIORITY ACTION WRITTEN
Friday, April 1, 2016ASSIGNED TO EXAMINER
Wednesday, March 23, 2016NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM
Tuesday, March 22, 2016NEW APPLICATION ENTERED IN TRAM

Related Keywords

glymaxan diseases gastrointestinal disorders system immunosuppressant corticosteroids endocrinology oncology syndrome metabolic